Patient Resources | Nivestym® (filgrastim-aafi) Site | Safety Info
Resources available to help support patients prescribed NIVESTYM
Making your support needs a priority. Together.
At Pfizer Oncology TogetherTM, we treat your individual needs as a priority. We’ll help you identify financial assistance options so you can get your prescribed NIVESTYM. We can also connect you with a dedicated Care Champion who has social work experience and will offer resources that may help with some of your day-to-day challenges.
Finding financial support options. Together.
Care Champion Support
At Pfizer Oncology Together, our Care Champions, who have social work experience, can provide you resources that may help with some of your day-to-day challenges||:
Connections to emotional support resources
Educational information about physical and mental health, nutrition, and NIVESTYM
Information to help you prepare for leaving or returning to work
Connections to independent organizations that help eligible patients find free rides and lodging for treatment-related appointments
A free app designed to help manage life with cancer
Whether you're living with cancer or want to support someone who is, LivingWithTM, a free app developed by Pfizer Oncology, may help you stay connected and organized, all in one place.
Available in English and Spanish.
Download LivingWith for free.
*Terms and Conditions: By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:
- The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM® is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Program offer is not valid for cash-paying patients.
- With this program, eligible patients may pay as little as $0 co-pay per NIVESTYM treatment, subject to a maximum benefit of $10,000 per calendar year for out-of-pocket expenses for NIVESTYM including co-pays or coinsurances.
- The amount of any benefit is the difference between your co-pay and $0.
- After the maximum of $10,000 you will be responsible for the remaining monthly out-of-pocket costs.
- Patient must have private insurance with coverage of NIVESTYM.
- This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs.
- You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
- You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required.
- You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs.
- This program is not valid where prohibited by law.
- This program cannot be combined with any other savings, free trial or similar offer for the specified prescription.
- Co-pay card will be accepted only at participating pharmacies.
- This program is not health insurance.
- This program is good only in the U.S. and Puerto Rico.
- This program is limited to 1 per person during this offering period and is not transferable.
- No other purchase is necessary.
- Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke or amend this program without notice.
- This program may not be available to patients in all states.
- For more information about Pfizer, visit www.pfizer.com.
- For more information about the Pfizer Oncology Together Co-Pay Savings Program for Injectables, visit pfizeroncologytogether.com, call 1-877-744-5675, or write to
Pfizer Oncology Together Co-Pay Savings Program for Injectables
P.O. Box 220366
Charlotte, NC 28222 - Program terms and offer will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.
†For patients to be eligible for the Injectables Co-Pay Program for NIVESTYM, they must have commercial insurance that covers NIVESTYM and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for NIVESTYM benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NIVESTYM administered in the outpatient setting.
‡The Injectables Co-Pay Program for NIVESTYM will pay the co-pay for NIVESTYM up to the annual assistance limit of $10,000 per calendar year per patient.
§If support from independent charitable foundations or Medicare Extra Help is not available, Pfizer Oncology Together will provide eligible patients with medication for free through the Pfizer Patient Assistance Program. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance FoundationTM. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
||Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Do not take NIVESTYM® if you have had a serious allergic reaction to human granulocyte-colony stimulating factors (G-CSFs) such as filgrastim products or pegfilgrastim products.
Before you take NIVESTYM®, tell your healthcare provider about all of your medical conditions, including if you:
- have a sickle cell disorder
- have kidney problems
- are receiving radiation therapy
- are pregnant or plan to become pregnant. It is not known if NIVESTYM® will harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if NIVESTYM® passes into your breast milk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive NIVESTYM®?
- NIVESTYM® injections can be given by a healthcare provider by intravenous (IV) infusion or under your skin (subcutaneous injection). Your healthcare provider may decide that subcutaneous injections can be given at home by you or your caregiver. If NIVESTYM® is given at home, see the detailed “Instructions for Use” that comes with your NIVESTYM® prescription for information on how to prepare and inject a dose of NIVESTYM®
- Your healthcare provider should show you and your caregiver how to prepare and inject NIVESTYM® before you use it
- You should not try to inject a dose of NIVESTYM® less than 0.3 mL (180 mcg) from a NIVESTYM® prefilled syringe. A dose less than 0.3 mL cannot be accurately measured using the NIVESTYM® prefilled syringe
- Your healthcare provider will tell you how much NIVESTYM® to inject and when to inject it. Do not change your dose or stop NIVESTYM® unless your healthcare provider tells you
- If you are receiving NIVESTYM® because you are also receiving chemotherapy, your dose of NIVESTYM® should be injected at least 24 hours before or 24 hours after your dose of chemotherapy. Your healthcare provider will do blood tests to monitor your white blood cell count, and if necessary, adjust your NIVESTYM® dose
- If you miss a dose of NIVESTYM®, talk to your healthcare provider about when you should have your next dose
What are the possible side effects of NIVESTYM®?
NIVESTYM® may cause serious side effects, including:
- Spleen rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach (abdomen) area or your left shoulder
- A serious lung problem called acute respiratory distress syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing
- Serious allergic reactions. NIVESTYM® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using NIVESTYM® and call your healthcare provider or get emergency medical help right away
- Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive NIVESTYM®. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing
- Kidney injury (glomerulonephritis). NIVESTYM® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
- swelling of your face or ankles
- blood in your urine or dark-colored urine
- you urinate less than usual
- Capillary leak syndrome. NIVESTYM® can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “capillary leak syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life threatening. Get emergency medical help right away if you develop any of the following symptoms:
- swelling or puffiness and are urinating less than usual
- trouble breathing
- swelling of your stomach area (abdomen) and feeling of fullness
- dizziness or feeling faint
- a general feeling of tiredness
- Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML):
- NIVESTYM® may increase the risk of developing a precancerous condition called MDS or a type of blood cancer called AML in people who were born with low white blood cell counts (congenital neutropenia)
- If you have breast cancer or lung cancer, when NIVESTYM® is used with chemotherapy and radiation therapy, or with radiation therapy only, you may have an increased risk of developing MDS or AML
- Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding
- Call your healthcare provider if you develop any of these symptoms during treatment with NIVESTYM®
- Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with NIVESTYM®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with NIVESTYM®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot
- Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with NIVESTYM®
- Inflammation of your blood vessels (cutaneous vasculitis). Tell your healthcare provider right away if you develop purple spots or redness of your skin
- Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received NIVESTYM®. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms
The most common side effects experienced in patients receiving NIVESTYM® include:
- Patients with cancer receiving chemotherapy: fever, pain, rash, cough, and shortness of breath
- Patients with AML receiving chemotherapy: pain, nose bleed, and rash
- Patients with cancer receiving chemotherapy followed by bone marrow transplant: rash
- Patients who are having their own blood cells collected: bone pain, fever, and headache
- Patients with severe chronic neutropenia: pain, decreased red blood cells, nose bleed, diarrhea, reduced sensation, and hair loss
These are not all the possible side effects of NIVESTYM®. Call your healthcare provider for medical advice about side effects.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
INDICATIONS
Patients With Cancer Receiving Myelosuppressive Chemotherapy
- NIVESTYM® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
- NIVESTYM® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
Patients With Cancer Undergoing Bone Marrow Transplantation
- NIVESTYM® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation
Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
- NIVESTYM® is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
Patients With Severe Chronic Neutropenia
- NIVESTYM® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
Please see full Prescribing Information and Patient Information for NIVESTYM®.
NIVESTYM is a registered trademark of Pfizer Inc.
Neupogen is a registered trademark of Amgen Inc.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Do not take NIVESTYM® if you have had a serious allergic reaction to human granulocyte-colony stimulating factors (G-CSFs) such as filgrastim products or pegfilgrastim products.
Before you take NIVESTYM®, tell your healthcare provider about all of your medical conditions, including if you:
- have a sickle cell disorder
- have kidney problems
- are receiving radiation therapy
- are pregnant or plan to become pregnant. It is not known if NIVESTYM® will harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if NIVESTYM® passes into your breast milk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive NIVESTYM®?
- NIVESTYM® injections can be given by a healthcare provider by intravenous (IV) infusion or under your skin (subcutaneous injection). Your healthcare provider may decide that subcutaneous injections can be given at home by you or your caregiver. If NIVESTYM® is given at home, see the detailed “Instructions for Use” that comes with your NIVESTYM® prescription for information on how to prepare and inject a dose of NIVESTYM®
- Your healthcare provider should show you and your caregiver how to prepare and inject NIVESTYM® before you use it
- You should not try to inject a dose of NIVESTYM® less than 0.3 mL (180 mcg) from a NIVESTYM® prefilled syringe. A dose less than 0.3 mL cannot be accurately measured using the NIVESTYM® prefilled syringe
- Your healthcare provider will tell you how much NIVESTYM® to inject and when to inject it. Do not change your dose or stop NIVESTYM® unless your healthcare provider tells you
- If you are receiving NIVESTYM® because you are also receiving chemotherapy, your dose of NIVESTYM® should be injected at least 24 hours before or 24 hours after your dose of chemotherapy. Your healthcare provider will do blood tests to monitor your white blood cell count, and if necessary, adjust your NIVESTYM® dose
- If you miss a dose of NIVESTYM®, talk to your healthcare provider about when you should have your next dose
What are the possible side effects of NIVESTYM®?
NIVESTYM® may cause serious side effects, including:
- Spleen rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach (abdomen) area or your left shoulder
- A serious lung problem called acute respiratory distress syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing
- Serious allergic reactions. NIVESTYM® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using NIVESTYM® and call your healthcare provider or get emergency medical help right away
- Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive NIVESTYM®. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing
- Kidney injury (glomerulonephritis). NIVESTYM® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
- swelling of your face or ankles
- blood in your urine or dark-colored urine
- you urinate less than usual
- Capillary leak syndrome. NIVESTYM® can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “capillary leak syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life threatening. Get emergency medical help right away if you develop any of the following symptoms:
- swelling or puffiness and are urinating less than usual
- trouble breathing
- swelling of your stomach area (abdomen) and feeling of fullness
- dizziness or feeling faint
- a general feeling of tiredness
- Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML):
- NIVESTYM® may increase the risk of developing a precancerous condition called MDS or a type of blood cancer called AML in people who were born with low white blood cell counts (congenital neutropenia)
- If you have breast cancer or lung cancer, when NIVESTYM® is used with chemotherapy and radiation therapy, or with radiation therapy only, you may have an increased risk of developing MDS or AML
- Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding
- Call your healthcare provider if you develop any of these symptoms during treatment with NIVESTYM®
- Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with NIVESTYM®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with NIVESTYM®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot
- Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with NIVESTYM®
- Inflammation of your blood vessels (cutaneous vasculitis). Tell your healthcare provider right away if you develop purple spots or redness of your skin
- Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received NIVESTYM®. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms
The most common side effects experienced in patients receiving NIVESTYM® include:
- Patients with cancer receiving chemotherapy: fever, pain, rash, cough, and shortness of breath
- Patients with AML receiving chemotherapy: pain, nose bleed, and rash
- Patients with cancer receiving chemotherapy followed by bone marrow transplant: rash
- Patients who are having their own blood cells collected: bone pain, fever, and headache
- Patients with severe chronic neutropenia: pain, decreased red blood cells, nose bleed, diarrhea, reduced sensation, and hair loss
These are not all the possible side effects of NIVESTYM®. Call your healthcare provider for medical advice about side effects.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
INDICATIONS
Patients With Cancer Receiving Myelosuppressive Chemotherapy
- NIVESTYM® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
- NIVESTYM® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
Patients With Cancer Undergoing Bone Marrow Transplantation
- NIVESTYM® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation
Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
- NIVESTYM® is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
Patients With Severe Chronic Neutropenia
- NIVESTYM® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
Please see full Prescribing Information and Patient Information for NIVESTYM®.
NIVESTYM is a registered trademark of Pfizer Inc.
Neupogen is registered a trademark of Amgen Inc.